 This study is a Phase I-II, multi-center, prospective, open-label, single-arm, clinical trial to evaluate PK, efficacy, and safety of human plasma-derived fibrinogen concentrate FIB Grifols in adult and pediatric patients with congenital afibrinogenaemia. 